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After more than 30 years of clinical and translational research, and having
contributed to large randomized international clinical trials in gynecologic cancer,
the multidisciplinary EORTC Gynecologic Cancer Group (GCG) currently is dealing
with one of the greatest challenges in cancer research, which is to discover and
establish clinically useful predictive and prognostic factors, to identify subgroups of
patients based on genomic patterns and activated pathways and to design clinical
trials appropriate for such subgroups. EORTC GCG current and future research has
to include the validation of prognostic and predictive markers, the identiﬁcation of
novel therapies that target speciﬁc pathways, and a better understanding of the
molecular basis for resistance. These studies will require the collection of large
numbers of biologic specimens, both at time of diagnosis and at time of recurrence
and, whenever possible, during treatment. These objectives can only be reached with
transversal cooperation within the EORTC framework (Pathobiology group, Imaging
group, etc.), as well as international cooperation. Support from private industry will
also be important in the context of a high-standard cooperation among industry
and academia. The EORTC with its unique multidisciplinary infrastructure and long
experience in cancer research is taking part through the EORTC GCG in international
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networks focused on gynecological cancer research on a large scale. Intergroup
collaboration and international contribution to establish the current and future
world-wide standards of care is also a priority for the GCG. The GCG also has a good
track record in rare tumors and will continue working on rare diseases along with
international partners.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
The EORTC Gynecological Cancer Group (GCG) is a multi-
disciplinary clinical disease oriented group composed of
gynecological oncologists, clinical/medical oncologists,
scientists, radiation oncologists and pathologists to-
gether with a number of data managers/trial coordina-
tors and nurses from 92 centers across Europe and other
countries. The GCG has conducted more than 60 large
clinical trials in a variety of gynecological cancers over
the last 35 years (Figs. 1,2). This paper will highlight the
most marking trials conducted by the GCG that have
played, and will play, a signiﬁcant role in the ﬁeld of
(therapy innovation for) gynecological cancers.
2. Ovarian cancer
2.1. Adjuvant chemotherapy in early-stage ovarian cancer
patients
Whilst some important studies were carried out in
the 1980’s it was really in the 1990’s that signiﬁcant
protocols came into being which led to an impact on
treatment delivery. Arguably one of the most important
Fig. 1 – Summary of GCG scientiﬁc activities over the
period 1977–2012. The number of studies includes six
trials (55092, 55102, 55111 and three initiatives in rare
tumors) recently opened or soon to be opened in 2012.
The number of publications includes peer-reviewed articles
only. Representation at important congresses is reﬂected by
the number of oral presentations.
Fig. 2 – Patient accrual in GCG studies is presented per
decade and includes recruitment numbers from other
collaborative groups in case of intergroup trials.
of these was the ACTION Study (EORTC 55904) which
investigated the role of adjuvant chemotherapy in early
ovarian cancer. The ACTION study was a randomized
clinical trial in 448 early ovarian cancer patients,
International Federation of Gynecology and Obstetrics
(FIGO) stage I and IIa, comparing adjuvant chemotherapy
to no further treatment after surgery. In the original
analysis, adjuvant chemotherapy improved recurrence-
free survival (RFS) but not overall survival (OS). 1 The
patients who received adjuvant chemotherapy had better
RFS than patients who were allocated to the observation
arm, with a hazard ratio (HR) equal to 0.63 (95%CI:
0.43−0.92, p=0.02). A similar trial carried out by the
Medical Research Council (MRC), the ICON-1 study,
demonstrated that women with early-stage epithelial
ovarian cancer who received adjuvant chemotherapy
had better RFS and OS than women who did not. 2
A pre-planned combined analysis of these two parallel
randomized clinical trials (ACTION and ICON-1) was
published in 2003. In this analysis, the improvement in
RFS and OS after adjuvant chemotherapy was conﬁrmed.
A total of 924 patients were randomized. With over
four years median follow up for survivors, the HR for
RFS was 0.64 (95%CI: 0.50–0.82; P = 0.001) in favor of
adjuvant chemotherapy, with an absolute difference
of 11%. For OS, the HR was 0.67 (95%CI: 0.50–0.90;
P = 0.008) in favor of adjuvant chemotherapy. These
results translated into an absolute difference of 8% in
the adjuvant chemotherapy group, and indicated that
adjuvant platinum-containing chemotherapy improved
Open access under CC BY-NC-ND license.
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survival and disease-free survival. Subgroup analysis
provided no evidence of a difference in the size of
effect of chemotherapy on survival in any pretreatment
subcategory. 3
In the ACTION study, subgroup analysis showed that
the completeness of surgical staging was an independent
prognostic factor and that the beneﬁt of adjuvant
chemotherapy was mainly limited to patients who
underwent incomplete (non-optimal) surgical staging. 1
The long-term analysis with a median follow-up of 10.1
years conﬁrmed the main conclusions of the original
analysis. 4 A beneﬁt but no cancer-speciﬁc survival
beneﬁt of adjuvant chemotherapy was seen for the whole
ACTION study group. Completeness of surgical staging in
patients with early-stage ovarian cancer was found to be
statistically signiﬁcantly associated with better outcome
in the both the control and the chemotherapy group.
The beneﬁt from adjuvant chemotherapy in terms of
overall and RFS appeared to be most evident in patients
with non-optimal surgical staging, and this held as well
for patients with a grade 3 tumor. 1,4 There has been
some debate about the interpretation of the sub-analyses
of the ACTION trial. There remains discussion about
whether chemotherapy can be omitted in patients with
optimally staged early-stage ovarian cancer. Although
the beneﬁt from adjuvant chemotherapy appeared to
be predominantly effective in patients with non-optimal
surgical staging, presumably because these patients have
more risk of harboring unappreciated residual disease,
this subgroup analysis has to be interpreted with caution.
The limited sample size and the fact that the ACTION
trial was not speciﬁcally designed to compare different
surgical staging categories − the patients were not
prospectively stratiﬁed according to the various surgical
staging categories − cannot rule out a beneﬁt from
chemotherapy in the optimally staged patients.
2.2. Interval debulking surgery and neoadjuvant
chemotherapy in stage IIIC−IV ovarian cancer patients
The other important relatively early study within the GCG
was the Interval Debulking Study (IDS) in Ovarian Cancer
(EORTC 55865). This clinical trial included FIGO stage
IIb−IV patients and randomized patients with residual
disease either to complete 6 cycles of chemotherapy or
3 cycles of chemotherapy followed by interval debulking
surgery and additional 3 cycles of chemotherapy. This
study showed, and continues to show with over 10 years
follow up, that there is a signiﬁcant survival advantage to
the patients who underwent IDS 5 (Fig. 3). This has been
disputed by some, particularly as the GOG 158 protocol
in the USA showed no beneﬁt of interval debulking
surgery. However there were some signiﬁcant differences
in the entry criteria and also the specialization of the
surgeon. In the GOG study all patients were operated by
gynecological oncologists but in the EORTC there was
Fig. 3 – Survival curve for patients who underwent
debulking surgery and for those who did not (ﬁgure
published by courtesy of van der Burg).
a mixture of general gynecologists and gynecological
oncologists. In addition, in GOG158 a maximal surgical
effort at primary surgery was required for inclusion,
which was not needed for inclusion in the EORTC
study. Many oncologists have interpreted these results as
showing that when an initial surgery has been performed
by a gynecological oncologist then IDS probably has a
minimal role to play, in all other cases interval debulking
surgery is of beneﬁt. This study also has helped to
promote referral of women with gynecological cancers
to specialist gynecological oncologists.
In September 2010 the EORTC 55971/NCIC-CTG OV13
trial (conventional surgery followed by chemotherapy
with or without interval debulking was compared with
neoadjuvant chemotherapy and delayed primary surgery
in stage IIIC and stage IV ovarian cancer) was honored
with a landmark paper from Dr Ignace Vergote and
EORTC/NCI-C collaborators in the New England Journal
of Medicine. 6 The importance of primary cytoreductive
surgery in the treatment of advanced ovarian cancer
FIGO stage IIIc and IV was already suggested as early as
1934, but it was not until the 1970’s that the amount of
residual tumor following primary surgery was shown to
be an important prognostic factor in advanced ovarian
carcinoma. Leaving no residual tumor following primary
debulking surgery has been shown to be the single most
important independent prognostic factor in advanced
ovarian carcinoma inmany prospective and retrospective
studies.
Recently, many institutions have switched to using
neoadjuvant chemotherapy in patients with advanced
ovarian cancer (without primary attempt of debulking)
followed by an interval debulking surgery (usually
after three courses of chemotherapy). The advantages
of neoadjuvant chemotherapy include an increased
rate of optimal surgery, reduced blood loss, lower
morbidity, shortened hospital stay, improved quality
of life, and acting as a mechanism to select out
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Fig. 4 – Kaplan–Meier plot for overall survival in neoadjuvant chemotherapy or primary surgery in Stage IIIc and IV ovarian
cancer (EORTC 55971). 6
patients with platinum resistance. Although there was
evidence from retrospective studies that neoadjuvant
chemotherapy followed by interval debulking surgery
was a valid alternative in a selected group of patients
with stage IIIc or IV ovarian carcinoma, this was
only recently conﬁrmed in this prospective randomized
trial performed by the EORTC-GCG in cooperation
with the NCIC-CTG. The objective of the EORTC-GCG
55971/INCIC-CTG trial 0VO16 was to compare primary
debulking surgery (PDS) followed by6 courses of platin-
based chemotherapy (CT) (Arm A) with 3 courses of
neoadjuvant chemotherapy (NACT), interval debulking
surgery (IDS) and another 3 courses of CT (Arm B)
in Stage IIIc−IV ovarian, fallopian tube or peritoneal
carcinoma (OVCA). To be eligible the patients needed
to have biopsy-proven OVCA; or ﬁne needle aspiration
suggesting the presence of OVCA, in combination with
a pelvic mass, presence of metastases of 2 cm outside
the pelvis and a CA125:CEA ratio 25. Non-inferiority for
OS (one-sided type I error 0.05, power 80%) required 704
patients.
Between September 1998 and December 2006, 718
patients were randomized. The baseline characteristics
for arms A and B were similar. The intention to treat
analysis showed a similar OS (Fig. 4) and progression-free
survival (PFS). The per- and post-operative complications
were lower in the neoadjuvant arm than in the primary
debulking arm. In the multivariate analyses complete
resection of all macroscopic lesions was the strongest
independent prognostic factor for OS. The timing of this
procedure (PDS or IDS) did not seem to play a role in the
group of patients as included in the study. In this respect
it should be mentioned that most patients included in
this trial had an extensive stage IIIc−IV disease. This
study showed that neoadjuvant chemotherapy followed
by interval debulking surgery is a good alternative for
primary debulking surgery in patients with extensive
stage IIIc or IV ovarian carcinoma, as included in the
study. Less per- and post-operative complications were
observed in the neoadjuvant arm compared to the
primary debulking arm. 6 The results of the trial are not
applicable to patients with lower stage disease (IIb−IIIb).
Furthermore, the authors highlighted that in patients
with a relatively limited stage IIIc or IV disease, which
can easily be resected to no residual tumor, primary
debulking surgery remains the preferred recommended
option.
Based on this platform, the EORTC GCG is looking at
a newly comprehensive trial in which novel targeted
agents can be tested in this group of patients with
Stage IIIc and IV disease. There is a unique opportunity
to collect tissue specimens before and after therapy
and also to evaluate complex functional imaging
techniques.
2.3. CA125 intervention study in collaboration with the
MRC/NCRI
Results of another practice-changing trial, MRC 0VO5/
EORTC 55955, a randomized trial in relapsed ovarian
cancer of early treatment based on conﬁrmed elevation
of CA125 versus delayed treatment based on clinical
relapse, were recently published. 7 Serum CA125 often
rises several months before women with ovarian
cancer have clinical/symptomatic relapse. MRC OV05/
EORTC 55955 investigated whether there were beneﬁts
from early treatment based on conﬁrmed elevation
of CA125 versus delaying treatment until clinically
indicated. Women with ovarian cancer in complete
remission after ﬁrst-line platinum-based chemotherapy
and a normal CA125 were registered. Every 3 months
CA125 was measured and monitored by coordinating
centers, and a general and gynecological examination
was performed; patients and investigators were blinded
to CA125 results. If CA125 levels exceeded twice the
upper limit of normal, patients were randomized to early
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Fig. 5 – Kaplan–Meier plot for overall survival in early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC
55955). 7
chemotherapy or delayed chemotherapy (continuing
blinded CA125 with treatment commencing if clinical/
symptomatic recurrence). All patients were treated
according to standard local practice. 1442 patients were
registered and 529 randomized (265 early, 264 delayed).
The EORTC GCG contributed substantially to this study
with 298 patients included. Baseline characteristics were
well balanced between randomized groups; their median
age at registration was 61 years; 81% had FIGO stage
III/IV disease. Second-line and third-line chemotherapy
started a median of 4.8 months and 4.6 months sooner
in the early arm.With a median follow up of 56.9 months
from randomization and 370 deaths, there was no
evidence of a difference in OS between the early and
delayed arms (Fig. 5), HR=0.98 (95%CI: 0.80–1.20), p = 0.85,
nor improvement in quality of life.
The conclusion was that there is no evidence of
a survival beneﬁt or better quality of life with early
treatment of relapse based on a raised CA125 level alone,
and therefore no value in the routine measurement of
CA125 in the follow-up of ovarian cancer patients who
attain a complete response after ﬁrst-line treatment.
This is the most solid evidence coming from a
randomized trial; however, we have to take into account
some limitations: in this study the role of secondary
cytoreduction was not considered. In the near future,
a better understanding of ovarian cancer biology, more
sensitive diagnostic techniques, more accurate surgical
procedures along with the availability of new compounds
will probably improve prognosis. In this scenario, the
anticipation of salvage therapy might play a different
role. In addition, the role of treatment on the basis of
CA125 increase at second or later relapse needs to be
established.
2.4. Other highlights in ovarian cancer
The EORTC GCG conducted the ﬁrst targeted agent
maintenance trial amongst all EORTC disease groups
(EORTC 55041). An extensive part consists of translational
research in this trial where a comparison between two
years of daily erlotinib versus observation is made
in patients with no evidence of disease progression
after ﬁrst-line, platinum-based chemotherapy for high-
risk stage I and stage II−IV ovarian epithelial, primary
peritoneal, or fallopian tube cancer. The results of this
intergroup randomized trial are expected to be published
soon.
In a randomized phase III European–Canadian inter-
group trial in ﬁrst-line setting (EORTC 55931) where
cisplatin–paclitaxel was compared to cisplatin–cyclo-
phosphamide, a signiﬁcant improvement for the pacli-
taxel regimen was shown in PFS and OS, conﬁrming
the GOG111 study results. 8 In addition, the survival
superiority of the paclitaxel regimen was conﬁrmed in
the long-term follow up results. 9
Worthwhile to mention are certainly a few trials
conducted by the group which failed to secure their
assumptions of changing treatment standards. The
randomized phase III trial in ﬁrst-line setting in which
sequential cisplatin/topotecan followed by paclitaxel/
carboplatin was compared with paclitaxel/carboplatin
only therapy − EORTC 55012/NCIC-CTG OV16/GEICO-001
led by the Canadian group − has recently published the
results of the PFS primary endpoint. The conclusion of
this trial with 819 patients with advanced epithelial ovar-
ian cancer was that sequential therapy was more toxic
than the standard arm, without improved efﬁcacy. 10 The
next analysis with the required 631 events for OS will be
carried out in due time.
In another trial (EORTC 55875: Intraperitoneal cisplatin
versus no further treatment: A phase III study in
ovarian cancer patients with a pathologically complete
remission after platinum-based induction chemotherapy
and cytoreductive surgery) intraperitoneal chemotherapy
as consolidation therapy was not different (both PFS and
OS) compared to observation and as such did not support
a change in clinical practice. 11
Another interesting trial was the LOROCSON study
(EORTC 55963: A randomized phase III study in Late Onset
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Table 1 – Treatment optimization trials in cervix cancer (published EORTC studies)
# Study title Eligible
patients
Main results
55802 12 Phase II trial of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in
disseminated squamous cell carcinoma of the uterine cervix
50 Response: 40%
median survival 37 wks
55832 13 Phase II study of mitomycin C - cisplatin in disseminated squamous cell
carcinoma of the uterine cervix
33 ORR: 42%
median duration 7.9 mo
55851 14 Phase II trial of a combination of vindesine, cisplatin, bleomycin, and
mitomycin-C (BEMP) in disseminated squamous cell carcinoma of the
uterine cervix
161 ORR: 45%
median duration 7.6 mo
Best prognosis in pts with good PS
and only metastatic disease
55863 15 Randomized phase III trial of vindesine, cisplatin, bleomycin and
mitomycin-C (BEMP) versus cisplatin (P) in disseminated squamous cell
carcinoma of the uterine cervix
235 BEMP vs. P
ORR: 45% vs. 25%
OS: 10.1 vs. 9.3 mo (NS)
BEMP: higher toxicity
55835 16 Phase II study of bromocriptine in the treatment of patients with
carcinoma of the cervix
18 ORR: 28%
55842 17 Phase II trial of 4′-epiDoxorubicin in disseminated carcinoma of the uterine
cervix
24 Partial Response: 4%
median duration 23 wks
55857 18 Phase II trial of 5-aza-2′-deoxycytidine in patients with advanced or
recurrent squamous cell carcinoma of the uterine cervix
15 No remission
55883 19 Phase II study of Navelbine in patients with advanced and/or recurrent
cervical carcinoma
41 Partial Response: 17%
median duration 5 mo
Recurrent Ovarian Cancer: Surgery Or Not; patients were
randomized between chemotherapy with or without
IDS), probably ahead of its time and a regrettable lost
opportunity to lead the world with treatment modality
trial(s). The concept of this trial was picked up by the
German national group and the DESKTOP trial series is
currently successfully recruiting.
3. Cervix carcinoma
The GCG has a long history of successful trials in cervical
cancer and is ﬁnalizing a randomized phase III study of
neoadjuvant chemotherapy followed by surgery versus
concomitant radiotherapy and chemotherapy in FIGO
Ib2, IIa>4 cm or IIb cervical cancer (EORTC 55994). This
trial is of utmost importance as today the scientiﬁc
community is eager to learn about the best treatment
modality in this early-stage population.
Not all of these trials have led to practice-changing
treatments and some investigational therapies were
found to be inactive in this disease. However, the trials
listed in Table 1, some in collaboration with other groups,
demonstrate that the GCG has invested much effort in
optimizing treatments especially in advanced metastatic
cervical cancer.
4. Corpus tumors
Tumors of the uterus have been explored by the GCG
over the last decades. Most of these trials were pure
academic trials, but remarkably these trials were done
with great enthusiasm and quality amongst the different
members.
An ambitious trial initially conceived by Dr Nina
Einhorn and completed by Dr Nick Reed and colleagues is
certainly the work in uterine sarcomas. The role of post-
surgical radiotherapy has long remained controversial in
the management of this disease. The EORTC performed
a randomized phase III trial in stage I and II uterine
sarcomas to evaluate a potential beneﬁt of adjuvant ra-
diotherapy in this population. Over a 13-year period, this
study recruited 224 patients including 103 leiomyosar-
comas (LMS) followed by 91 carcinosarcomas (CS) and
28 endometrial stromal sarcomas. The beneﬁt in local
control for CS (not seen in LMS) did not translate
into any difference in OS between immediate post-
operative pelvic radiotherapy and observation. These
results clearly demonstrated that women with uterine
sarcomas can be spared adjuvant radiotherapy. 20
The group studied different chemotherapy regimens in
advanced and/or recurrent endometrial cancer (EORTC
trials 55872, 55873 and 55984). The combination regimen
of adriamycin/cisplatin was superior to adriamycin
alone with a modest survival beneﬁt, 21 and the trial
with second-line cyclophosphamide versus ifosfamide −
showing superiority of the latter − demonstrated that
cyclophosphamide was not an active drug at all for this
disease. 22 The results of the trial comparing TAP versus
AP are expected to be published.
A cornerstone of endometrial carcinoma treatment
consists of radical hysterectomy and bilateral salpingec-
tomy and oophorectomy (BSO) followed by adjuvant
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Table 2 – EORTC GCG involvement in rare gynecological tumors
Disease EORTC trial number(s) Eligible patients
Advanced vulvar cancer 33−35 55831, 55871, 55985 85
Granulosa theca cell tumor 36 55843 38
Uterine sarcomas (LMS, CS, ESS) 20 55874 224
Carcinosarcoma (malignant mixed mesodermal tumors) 37 55923 41
Dysgerminoma 38 55862 18
Clear cell carcinoma in early ovarian cancer 39 55904 − ACTION 63
treatment in case of high risk of recurrences. To
avoid over- and under-treatment, it is extremely
important to know the different risk factors and the
effect of post-operative radiotherapy, chemotherapy,
and hormonotherapy. The problem is that even today,
appropriate tailoring for each woman is not possible
due to controversies which exist for some treatments.
Further research is required to ﬁnd optimal treatment
with emphasis on survival and quality of life. 23 In
response to the current lack of a consensus approach
in endometrial cancer, various academic institutions
discussed and analyzed the pertinent problems in the
treatment of women with endometrial cancer and
designed the NEtwork STudy in Endometrial Cancer
(NESTEC). This academic platform will try to answer four
main questions: (1) Does proper lymph node excision
improve survival? (2) Is there a need for post-operative
chemotherapy in high-risk early-stage patients without
metastasis to the lymph nodes? (3) Is post-operative
chemotherapy followed by radiation therapy better than
chemotherapy alone in high-risk early-stage patients
with unknown lymph node involvement? (4) Are new
chemotherapeutic regimens better than the standard
combination chemotherapy in prolonging survival of
advanced/relapsed disease? The EORTC GCG is on the
verge to start the 55102 trial (A phase III trial of
postoperative chemotherapy or no further treatment for
patients with node-negative stage I−II intermediate or
high risk endometrial cancer) in collaboration with the
Danish Gynecological Cancer Group and other European
Network of Gynecological Oncological Trial (ENGOT)
groups in order to answer the second question.
Collaboration with the EORTC Quality of Life Group
resulted in the publication in 2011 of the validated
endometrial module (QLQ-EN24) questionnaire, a sup-
plement to the EORTC QLQ-C30 core questionnaire
developed by Dr Eva Greimel and her group. 24 The EORTC
55102 trial will be the ﬁrst phase III trial implementing
this endometrial module. Similar validated supplemental
modules for ovarian (QLQ-OV28) and cervical (QLQ-CX24)
cancer were published respectively in 2003 and 2006. 25,26
Together with the GCG members a new vulva cancer QoL
module is currently under development.
5. Translational research
The group has a very good track record of translational
research projects, certainly in the merit of Dr John
Green, with publications dating back to 1997. 27 Currently
the GCG TR committee is chaired by Dr Els Berns and
Dr Maria van der Burg, who have expanded the portfolio
of projects in the last years.
Two GCG translational research applications were
awarded in 2008 and 2009 during the EORTC strategy
meetings. The results of the ﬁrst one, from Dr Jozien
Helleman and Dr Els Berns, “Towards ovarian cancer
speciﬁc predictive signatures”, are currently submitted
for publication. A combined prognostic and predic-
tive assessment on the EORTC 55041 study is per-
formed by pharmacogenomic and immunohistochemical
evaluation of the EGFR pathway in ovarian cancer
patients treated with erlotinib in the 2009 awarded
work, “genetic signatures for prediction of platinum-
sensitivity in ovarian cancer” by Dr Evelyn Despierre and
Dr Ignace Vergote.
6. Quality control and quality assurance
A quality control and assurance program has been es-
tablished within different gynecological tumor domains.
Several papers have been published looking at general
approach of the gynecological oncology population 28,29
as well as speciﬁc topics, such as quality indicators
of radical hysterectomy in cervical and ovarian cancer
and the impact of the quality of pathology reports on
cancer care. 30−32
7. Rare tumors
As mentioned earlier, the GCG has been on the
frontline in cutting-edge clinical trials and has a
profound curriculum in rare gynecological tumors.
Table 2 summarizes the published EORTC trials within
different rare tumors. Most of the publications prior
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to these EORTC studies were based upon case studies,
therefore special acknowledgement is reserved for
these successful recruitment numbers and scientiﬁc
contributions towards a better understanding of the
disease as well as treatment optimization. Sadly, due
to changes in EU regulations, it is very challenging
to perform studies in these rare cancers unless they
are supported by the pharmaceutical industry. The GCG
would be well placed to take the lead in coordinating
and running these trials within Europe if it were given
the support to do so.
The GCG has played an instrumental role in the set up
of the Gynecologic Cancer Intergroup (GCIG). Not only
has the contribution over the years been crucial, but
also the fact that the group played a leading role in
its development, which is illustrated by the effort of
its ﬁrst Chair, Dr Jan Vermorken. Today, the GCIG is an
important platform by which new treatment options
can be brought to the patients in a much more rapid
manner. 40,41 The GCG is a vigorous contributor to ENGOT
to streamline and exchange creative ideas on performing
clinical trials between different collaborative groups.
Recently, the group was an active participant of the
newly established NCI/NCRN/EORTC International Rare
Cancers Initiative (IRCI). The latter cooperation led to a
portfolio of three possible clinical trials in gynecological
sarcomas which are, due its nature, only feasible to run
on a global level. The study proposals under development
are within the following diseases: early-stage high-
grade uLMS, high-grade uterine sarcoma, and low-grade
ESS and uLMS.
8. Current and future activities
The EORTC translational and imaging research processes
are now well established, and most of the future GCG
studies will provide the basis for molecular approaches to
the management of patients with gynecological cancers.
The group is currently focusing on identifying top
areas (targets, surgical or radiation issues) for future
clinical trials. Intergroup collaboration and international
contribution to establish the current and future world-
wide standards of care for patients with gynecological
malignancies is also a priority for the GCG. Finally the
GCG is well placed to be the key liaison for conducting
rare tumor trials and studies if given the resources and
support.
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